Skip to content
2000
Volume 23, Issue 1
  • ISSN: 1570-1638
  • E-ISSN: 1875-6220

Abstract

Introduction

This study, aimed to prepare a scientific report, underscores the pharmacotherapeutic aspects, including therapeutic indications, mechanisms of therapeutic action, pharmacokinetics, adverse reactions, safety in special cases, approximate costs, ., of USFDA-approved novel drugs in the year 2023 and serve as a treasured resource for academia, researchers, patients, and clinicians.

Methods

This comprehensive report was prepared by reviewing the pre-clinical and clinical data of the USFDA-approved novel drugs available in the public domain, especially on the website of the USFDA, National Library of Medicine, Clinical Trials, other online resources, and cross-references.

Results and Discussion

The USFDA has approved 55 novel drug therapies in the year 2023 and identified 38 drugs as new chemical entities (29 small molecules, 5 peptides, and 4 oligonucleotides) and 17 new biologicals. About 51% (28 out of 55) of drugs were recommended for rare diseases and designated as orphan drugs. In addition to the therapeutic aspects and general description, the approximate cost or price and safety studies in special cases such as lactating and pregnant women, pediatrics, and geriatrics of all novel drug therapies are meticulously presented in this study.

Conclusion

The novel drug therapies approved by the USFDA hold significant potential to enhance the patient’s care by providing advanced treatment modalities. This study, reporting the comprehensive description of therapeutic aspects of the mentioned new drug therapies, underscores the commitment of the pharmaceutical sector to address the unmet medical needs and reshape the landscape of the healthcare service system by instilling optimism among patients and healthcare providers.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cddt/10.2174/0115701638379447250526075127
2025-06-03
2026-03-07

  • From This Site

    /content/journals/cddt/10.2174/0115701638379447250526075127
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FrancoP. JainR. Rosenkrands-LangeE. HeyC. KobanM.U. Regulatory pathways supporting expedited drug development and approval in ICH member countries.Ther. Innov. Regul. Sci.202357348451410.1007/s43441‑022‑00480‑3 36463352
     [Google Scholar]
  2. GoyalP.K. ShekharS. RishiK. Hatch waxman act and generic drugs: A review.J. Pharm. Biomed. Sci.201182216
     [Google Scholar]
  3. RoskoskiR. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.Pharmacol. Res.202420010705910.1016/j.phrs.2024.107059 38216005
     [Google Scholar]
  4. de la TorreB.G. AlbericioF. The pharmaceutical industry in 2023: An analysis of FDA drug approvals from the perspective of molecules.Molecules202429358510.3390/molecules29030585 38338330
     [Google Scholar]
  5. WangY.T. YangP.C. ZhangY.F. SunJ.F. Synthesis and clinical application of new drugs approved by FDA in 2023.Eur. J. Med. Chem.202426511612410.1016/j.ejmech.2024.116124 38183778
     [Google Scholar]
  6. GoyalP.K. SangwanK. Pharmacological profile of FDA-approved orphan drugs in the year 2022.Curr. Pharmacol. Rep.20241029612010.1007/s40495‑024‑00351‑5
     [Google Scholar]
  7. KangC. Avacincaptad pegol: First approval.Drugs202383151447145310.1007/s40265‑023‑01948‑8 37814173
     [Google Scholar]
  8. HoyS.M. Bexagliflozin: First approval.Drugs202383544745310.1007/s40265‑023‑01848‑x 36867399
     [Google Scholar]
  9. G OliveiraD FariaR TorresT An overview of bimekizumab for the treatment of psoriatic arthritis: The evidence so far.Drug Des. Devel. Ther.202115151045105310.2147/DDDT.S267405 33727793
     [Google Scholar]
  10. RuggieroA. PotestioL. CamelaE. FabbrociniG. MegnaM. Bimekizumab for the treatment of psoriasis: A review of the current knowledge.Psoriasis (Auckl.)20221212713710.2147/PTT.S367744 35707807
     [Google Scholar]
  11. HeoY.A. Birch bark extract: A review in epidermolysis bullosa.Drugs202383141309131410.1007/s40265‑023‑01935‑z 37658982
     [Google Scholar]
  12. ShirleyM. Capivasertib: First approval.Drugs202484333734610.1007/s40265‑024‑01998‑6 38388873
     [Google Scholar]
  13. LabellaB. Cotti PiccinelliS. RisiB. A comprehensive update on late-onset pompe disease.Biomolecules2023139127910.3390/biom13091279 37759679
     [Google Scholar]
  14. DhillonS. Daprodustat: First approval.Drugs202080141491149710.1007/s40265‑020‑01384‑y 32880805
     [Google Scholar]
  15. BlairH.A. Efbemalenograstim alfa: First approval.Drugs202383121125113010.1007/s40265‑023‑01911‑7 37368138
     [Google Scholar]
  16. HoyS.M. Elacestrant: First approval.Drugs202383655556110.1007/s40265‑023‑01861‑0 37060385
     [Google Scholar]
  17. DhillonS. Elranatamab: First approval.Drugs202383171621162710.1007/s40265‑023‑01954‑w 37924427
     [Google Scholar]
  18. FramptonJ.E. Epcoritamab: First approval.Drugs202383141331134010.1007/s40265‑023‑01930‑4 37597091
     [Google Scholar]
  19. NieT. Eplontersen: First approval.Drugs202484447347810.1007/s40265‑024‑02008‑5 38413492
     [Google Scholar]
  20. ShirleyM. Etrasimod: First approval.Drugs202484224725410.1007/s40265‑024‑01997‑7 38388871
     [Google Scholar]
  21. LeeA. Fezolinetant: First approval.Drugs202383121137114110.1007/s40265‑023‑01917‑1 37462862
     [Google Scholar]
  22. HeoY.A. Flotufolastat F 18: Diagnostic first approval.Mol. Diagn. Ther.202327563163610.1007/s40291‑023‑00665‑y 37439946
     [Google Scholar]
  23. ShirleyM. Fruquintinib: First global approval.Drugs201878161757176110.1007/s40265‑018‑0998‑z 30357594
     [Google Scholar]
  24. KeamS.J. Gepirone extended-release: First approval.Drugs202383181723172810.1007/s40265‑023‑01975‑5 38079093
     [Google Scholar]
  25. ShirleyM. Glofitamab: First approval.Drugs2023831093594110.1007/s40265‑023‑01894‑5 37285013
     [Google Scholar]
  26. RizkD.V. RovinB.H. ZhangH. Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: Design and rationale of the APPLAUSE-IgAN study.Kidney Int. Rep.20238596897910.1016/j.ekir.2023.01.041 37180505
     [Google Scholar]
  27. GettmanL. Lecanemab-irmb (Leqembi™) for treatment of alzheimer’s disease.Sr. Care Pharm.2024392757710.4140/TCP.n.2024.75 38263569
     [Google Scholar]
  28. DugganS. Al-SalamaZ.T. Leniolisib: First approval.Drugs2023831094394810.1007/s40265‑023‑01895‑4 37256490
     [Google Scholar]
  29. SyedY.Y. Lotilaner ophthalmic solution 0.25%: First approval.Drugs202383161537154110.1007/s40265‑023‑01947‑9 37843754
     [Google Scholar]
  30. AschenbrennerD.S. Two new drugs for ulcerative colitis.Am. J. Nurs.20241243192010.1097/01.NAJ.0001008396.75301.5c 38386827
     [Google Scholar]
  31. KeamS.J. Momelotinib: First approval.Drugs202383181709171510.1007/s40265‑023‑01964‑8 37989928
     [Google Scholar]
  32. HoyS.M. Motixafortide: First approval.Drugs202383171635164310.1007/s40265‑023‑01962‑w 37996648
     [Google Scholar]
  33. SyedY.Y. Nedosiran: First approval.Drugs202383181729173310.1007/s40265‑023‑01976‑4 38060091
     [Google Scholar]
  34. LambY.N. Nirmatrelvir plus ritonavir: First approval.Drugs202282558559110.1007/s40265‑022‑01692‑5 35305258
     [Google Scholar]
  35. KeamS.J. Nirogacestat: First approval.Drugs202484335536110.1007/s40265‑024‑02002‑x 38409573
     [Google Scholar]
  36. LevienT.L. BakerD.E. Formulary drug reviews: Nirsevimab.Hosp. Pharm.202459213814510.1177/00185787231212620 38450347
     [Google Scholar]
  37. LeeA. Omaveloxolone: First approval.Drugs202383872572910.1007/s40265‑023‑01874‑9 37155124
     [Google Scholar]
  38. HoyS.M. Palovarotene: First approval.Drugs202282671171610.1007/s40265‑022‑01709‑z 35384641
     [Google Scholar]
  39. LinhartA. DostálováG. NichollsK. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.Orphanet J. Rare Dis.202318133210.1186/s13023‑023‑02937‑6 37865771
     [Google Scholar]
  40. SheppardJ.D. EvansD.G. ProtzkoE.E. A review of the first anti-evaporative prescription treatment for dry eye disease: Perfluorohexyloctane ophthalmic solution.Am. J. Manag. Care20232914S251S25910.37765/ajmc.2023.89464 37930231
     [Google Scholar]
  41. HeoY.A. Pirtobrutinib in relapsed or refractory mantle cell lymphoma: A profile of its use.Drugs Ther. Perspect.2024402455210.1007/s40267‑023‑01041‑w
     [Google Scholar]
  42. KeamS.J. Pirtobrutinib: First approval.Drugs202383654755310.1007/s40265‑023‑01860‑1 37004673
     [Google Scholar]
  43. HoyS.M. Pozelimab: First approval.Drugs202383161551155710.1007/s40265‑023‑01955‑9 37856038
     [Google Scholar]
  44. CortesJ. Quizartinib: A potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML.J. Hematol. Oncol.202417111110.1186/s13045‑024‑01617‑7 39538314
     [Google Scholar]
  45. DhillonS. Repotrectinib: First approval.Drugs202484223924610.1007/s40265‑023‑01990‑6 38279972
     [Google Scholar]
  46. KangC. Retifanlimab: First approval.Drugs202383873173710.1007/s40265‑023‑01884‑7 37184754
     [Google Scholar]
  47. SaadeddinA. PurohitV. HuhY. Virtual bioequivalence assessment of ritlecitinib capsules with incorporation of observed clinical variability using a physiologically based pharmacokinetic model.AAPS J.20242611710.1208/s12248‑024‑00888‑9 38267790
     [Google Scholar]
  48. BlairH.A. Ritlecitinib: First approval.Drugs202383141315132110.1007/s40265‑023‑01928‑y 37556041
     [Google Scholar]
  49. SyedY.Y. Rezafungin: First approval.Drugs202383983384010.1007/s40265‑023‑01891‑8 37212966
     [Google Scholar]
  50. HoyS.M. Rozanolixizumab: First approval.Drugs202383141341134710.1007/s40265‑023‑01933‑1 37656420
     [Google Scholar]
  51. LambY.N. Somatrogon: First approval.Drugs202282222723410.1007/s40265‑021‑01663‑2 35041176
     [Google Scholar]
  52. TalhaM. AliM.H. Latest FDA Approved drug Sotagliflozin (Inpefa): A glance at its prospectives for heart failure.Curr. Probl. Cardiol.2023481110189710.1016/j.cpcardiol.2023.101897 37402421
     [Google Scholar]
  53. SyedY.Y. Sparsentan: First approval.Drugs202383656356810.1007/s40265‑023‑01864‑x 37022667
     [Google Scholar]
  54. KeamS.J. Sulbactam/Durlobactam: First approval.Drugs202383131245125210.1007/s40265‑023‑01920‑6 37523122
     [Google Scholar]
  55. KeamS.J. Talquetamab: First approval.Drugs202383151439144510.1007/s40265‑023‑01945‑x 37792138
     [Google Scholar]
  56. LiuY. ZhangA.Q. CaoL. XiaH.T. MaJ.J. Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: A systematic review and meta-analysis of randomized controlled trials.PLoS One2013811e7941710.1371/journal.pone.0079417 24278133
     [Google Scholar]
  57. BlairH.A. Tofersen: First approval.Drugs202383111039104310.1007/s40265‑023‑01904‑6 37316681
     [Google Scholar]
  58. KeamS.J. Toripalimab: First global approval.Drugs201979557357810.1007/s40265‑019‑01076‑2 30805896
     [Google Scholar]
  59. HuduS.A. ElmigdadiF. QtaitatA.A. Trofinetide for Rett syndrome: Highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need.J. Clin. Med.20231215511410.3390/jcm12155114 37568516
     [Google Scholar]
  60. KeamS.J. Vamorolone: First approval.Drugs202484111111710.1007/s40265‑023‑01986‑2 38103149
     [Google Scholar]
  61. HarmatzP. CattaneoF. ArdigòD. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis.Mol. Genet. Metab.2018124215216010.1016/j.ymgme.2018.04.003 29716835
     [Google Scholar]
  62. DhillonS. Zavegepant: First approval.Drugs202383982583110.1007/s40265‑023‑01885‑6 37227596
     [Google Scholar]
  63. ShirleyM. Zilucoplan: First approval.Drugs20248419910410.1007/s40265‑023‑01977‑3 38093160
     [Google Scholar]
  64. HeoY.A. Zuranolone: First approval.Drugs202383161559156710.1007/s40265‑023‑01953‑x 37882942
     [Google Scholar]
  65. PatelS.S. LallyD.R. HsuJ. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.Eye (Lond.)202337173551355710.1038/s41433‑023‑02497‑w 36964259
     [Google Scholar]
  66. KhananiA.M. PatelS.S. StaurenghiG. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.Lancet2023402104111449145810.1016/S0140‑6736(23)01583‑0 37696275
     [Google Scholar]
  67. KhanN.A. ArifH. ImranL. The FDA has approved a new SGLT2 inhibitor, bexagliflozin, which is showing promising results in the management of type 2 diabetes.SN Compr. Clin. Med.20235121710.1007/s42399‑023‑01563‑4
     [Google Scholar]
  68. RedkarV. RedkarS. RedkarS. Bexagliflozin in patients with type 2 diabetes: Scoping review of the published randomised control trials.Endocrine Abstr202390348810.1530/endoabs.90.P348
     [Google Scholar]
  69. McInnesI.B. AsahinaA. CoatesL.C. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).Lancet2023710370253710.1016/S0140‑6736(22)02302‑9
     [Google Scholar]
  70. WarrenR.B. BlauveltA. BagelJ. Bimekizumab versus adalimumab in plaque psoriasis.N. Engl. J. Med.2021385213014110.1056/NEJMoa2102388 33891379
     [Google Scholar]
  71. KernJ.S. SprecherE. FernandezM.F. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: Results from the phase III randomized double-blind phase of the EASE study.Br. J. Dermatol.20231881122110.1093/bjd/ljac001 36689495
     [Google Scholar]
  72. KiritsiD. MurrellD.F. BrucknerA.L. Long-term safety and efficacy of Oleogel-S10 (birch triterpenes) in epidermolysis bullosa wounds: 24-month open-label data from the EASE study.Pediatr. Dermatol.202335ljaf02210.1093/bjd/ljaf022
     [Google Scholar]
  73. Schwieger-BrielA. OttH. KiritsiD. Laszczyk-LauerM. BodemerC. Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa.Dermatol. Ther.2019324e1298310.1111/dth.12983 31168940
     [Google Scholar]
  74. AbushanabA.K. MousaM.T. MustafaM.T. QawaqzehR.A. The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.Expert Opin. Drug Saf.202322979980510.1080/14740338.2023.2218085 37224269
     [Google Scholar]
  75. KillockD. AKT inhibition associated with improved OS.Nat. Rev. Clin. Oncol.202219956810.1038/s41571‑022‑00662‑w 35778610
     [Google Scholar]
  76. BlairH.A. Cipaglucosidase Alfa: First approval.Drugs202383873974510.1007/s40265‑023‑01886‑5 37184753
     [Google Scholar]
  77. HaiderM.U. FurqanM. MehmoodQ. Daprodustat: A potential game-changer in renal anemia therapy—A perspective.Front. Pharmacol.202314124949210.3389/fphar.2023.1249492 37637409
     [Google Scholar]
  78. GlaspyJ. BondarenkoI. BurdaevaO. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: Results of a phase III trial.Support. Care Cancer20243213410.1007/s00520‑023‑08176‑6 38103088
     [Google Scholar]
  79. BlayneyD.W. SchwartzbergL. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.Cancer Treat. Rev.202210910242710.1016/j.ctrv.2022.102427 35785754
     [Google Scholar]
  80. VarellaL. CristofanilliM. Evaluating elacestrant in the management of ER-positive, HER2-negative advanced breast cancer: evidence to date.OncoTargets Ther.20231618919610.2147/OTT.S400563 36993871
     [Google Scholar]
  81. LesokhinA.M. TomassonM.H. ArnulfB. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results.Nat. Med.20232992259226710.1038/s41591‑023‑02528‑9 37582952
     [Google Scholar]
  82. RiazR. KhanA. SiddiquiT. Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.Rare Tumors2023152036361323119356610.1177/20363613231193566 37534337
     [Google Scholar]
  83. CoelhoT. Waddington CruzM. ChaoC.C. Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen.Neurol. Ther.202312126728710.1007/s40120‑022‑00414‑z 36525140
     [Google Scholar]
  84. DiepJ.K. YuR.Z. VineyN.J. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis.Br. J. Clin. Pharmacol.202288125389539810.1111/bcp.15468 35869634
     [Google Scholar]
  85. MatsuokaK. HibiT. Etrasimod for ulcerative colitis: Evaluating phase III results.Nat. Rev. Gastroenterol. Hepatol.2023201276276310.1038/s41575‑023‑00793‑0 37221319
     [Google Scholar]
  86. SandbornW.J. VermeireS. Peyrin-BirouletL. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies.Lancet2023401103831159117110.1016/S0140‑6736(23)00061‑2 36871574
     [Google Scholar]
  87. LedermanS. OtteryF.D. CanoA. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): A phase 3 randomised controlled study.Lancet2023401103821091110210.1016/S0140‑6736(23)00085‑5 36924778
     [Google Scholar]
  88. DasariN.A. LonardiS. Garcia-CarboneroR. LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer.Ann. Oncol.202233S1391S139210.1016/j.annonc.2022.08.021
     [Google Scholar]
  89. JamesA.D. KulmatyckiK. PollerB. Absorption, distribution, metabolism, and excretion of [(14)C]iptacopan in healthy male volunteers and in vivo and in vitro studies.Drug Metab. Dispos.202351787388310.1124/dmd.123.001290 37308298
     [Google Scholar]
  90. LindorferM.A. PawluczkowyczA.W. PeekE.M. HickmanK. TaylorR.P. ParkerC.J. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: Both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.Blood2010115112283229110.1182/blood‑2009‑09‑244285 20068220
     [Google Scholar]
  91. HoyS.M. Lecanemab: First approval.Drugs202383435936510.1007/s40265‑023‑01851‑2 36856953
     [Google Scholar]
  92. D’HaensG. DubinskyM. KobayashiT. Mirikizumab as induction and maintenance therapy for ulcerative colitis.N. Engl. J. Med.2023388262444245510.1056/NEJMoa2207940 37379135
     [Google Scholar]
  93. VerstovsekS. GerdsA.T. VannucchiA.M. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase 3 study.Lancet20234011037326928010.1016/S0140‑6736(22)02036‑0 36709073
     [Google Scholar]
  94. KingwellK. γ-secretase inhibitor notches first approval.Nat. Rev. Drug Discov.2024231910.1038/d41573‑023‑00204‑8 38057455
     [Google Scholar]
  95. NazirA. FatimaR. NazirA. FDA grants approval to the RSV vaccine (nirsevimab-alip) for all infants: A leap forward for shielding the smallest.Int. J. Surg.2023109123745374610.1097/JS9.0000000000000698 38258995
     [Google Scholar]
  96. ZhouF. GeZ. ChenB. Quizartinib (AC220): A promising option for acute myeloid leukemia.Drug Des. Devel. Ther.2019131117112510.2147/DDDT.S198950 31114157
     [Google Scholar]
  97. AffanM. DarM.S. Sotagliflozin: An insight into the first dual SGLT inhibitor now approved for heart failure.Ir. J. Med. Sci.2024193266967010.1007/s11845‑023‑03474‑8 37523069
     [Google Scholar]
  98. MarkhamA. KeamS.J. Sotagliflozin: First global approval.Drugs20197991023102910.1007/s40265‑019‑01146‑5 31172412
     [Google Scholar]
  99. AgarwalA.K. Roy-ChaudhuryP. MountsP. HurlburtE. PfaffleA. PoggioE.C. Taurolidine/heparin lock solution and catheter-related bloodstream infection in hemodialysis: A randomized, double-blind, active-control, phase 3 study.Clin. J. Am. Soc. Nephrol.202318111446145510.2215/CJN.0000000000000278 37678222
     [Google Scholar]
  100. WangF.H. WeiX.L. FengJ. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02).J. Clin. Oncol.202139770471210.1200/JCO.20.02712 33492986
     [Google Scholar]
  101. KeamS.J. Trofinetide: First approval.Drugs202383981982410.1007/s40265‑023‑01883‑8 37191913
     [Google Scholar]
  102. AntanaskovićA. StevićI. GojakR. LakićD. JankovićS. Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis.Biotechnol. Biotechnol. Equip.2023371227157410.1080/13102818.2023.2271574
     [Google Scholar]
  103. SangwanK. GoyalP.K. SharmaV. Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: A comprehensive review.Naunyn Schmiedebergs Arch. Pharmacol.202510.1007/s00210‑025‑03961‑y 40067439
     [Google Scholar]
  104. DalalD. KantR. AttriK. A systematic overview of bexagliflozin: A type 2 diabetic drug.Asian J Pharm Res Health Care202315210911410.4103/ajprhc.ajprhc_25_23
     [Google Scholar]
  105. SangwanK. SharmaV. GoyalP.K. Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review.Curr. Mol. Med.202424673475010.2174/1566524023666230622151034 37350009
     [Google Scholar]
  106. LiuA. ZhaoJ. ShahM. Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: Design, development, and clinical studies.ACS Pharmacol. Transl. Sci.20225111007101610.1021/acsptsci.2c00110 36407951
     [Google Scholar]
  107. ThaçiD. VenderR. de RieM.A. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: Longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.Br. J. Dermatol.20231881223110.1093/bjd/ljac021 36689515
     [Google Scholar]
  108. KarpeckiP.M. SheppardJ.D. Perfluorohexyloctane ophthalmic solution: A review of a prescription treatment for dry eye disease that directly targets tear evaporation.Expert Rev. Ophthalmol.202318635536410.1080/17469899.2023.2275586
     [Google Scholar]
  109. EyreT.A. ShahN.N. DreylingM. BRUIN MCL-321: Phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.Future Oncol.202218363961396910.2217/fon‑2022‑0976 36377973
     [Google Scholar]
  110. Devalaraja-NarashimhaK. HuangC. CaoM. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates.PLoS One2022176e026974910.1371/journal.pone.0269749 35709087
     [Google Scholar]
  111. ShaukatA. KhanA. RiazR. BatoolU.E.A. MalikzaiA. Retifanlimab: A breakthrough for the management of Merkel cell carcinoma.Int. J. Surg. Oncol. (N.Y.)202383182010.1097/IJ9.0000000000000116
     [Google Scholar]
/content/journals/cddt/10.2174/0115701638379447250526075127
Loading
Pharmacological Insights on USFDA-approved Novel Drug Therapies in the Year 2023
Current Drug Discovery Technologies 23, E15701638379447 (2026); https://doi.org/10.2174/0115701638379447250526075127
/content/journals/cddt/10.2174/0115701638379447250526075127
/content/journals/cddt/10.2174/0115701638379447250526075127
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Elacestrant; fruquintinib; glofitamab-gxbm; nirogacestat; pozelimab-bbfg; vamorolone; zilucoplan

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test